NCT01392560已完成2 期
An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia
研究概览
简要总结
This open-label study aims to evaluate the impact of BI 10773 treatment on glomerular filtration rate under controlled conditions of euglycaemia and hyperglycaemia in subjects with type 1 diabetes mellitus with or without renal hyperfiltration and to characterize the safety and efficacy of BI 10773 25 mg QD as add-on therapy to insulin in these subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
BI 10773
Experimental
Oral once daily
干预措施: BI 10773 (Drug)
结局指标
主要结局
Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia
时间窗: Baseline and 8 weeks
The primary endpoint is change in glomerular filtration rate (GFR) after 8 weeks of treatment with empagliflozin under controlled conditions of euglycaemia and hyperglycaemia
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study on Delayed Graft Function Using Paired KidneysDelayed Graft FunctionNCT01561599Angion Biomedica Corp12
已完成
1 期
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.Diabetes Mellitus Type 2NCT00368368Hoffmann-La Roche5
已完成
1 期
Evaluation of Effect of Renal Impairment on the PK of Tenofovir ExalidexRenal ImpairmentNCT03284164ContraVir Pharmaceuticals, Inc.16
已完成
4 期
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected AdultsHIV-1 InfectionNCT02246998Gilead Sciences72
尚未招募
不适用
BB3 in Kidney Transplantation.End-stage renal diseasekidney transplantationnierfalenniertransplantatieNL-OMON22050Angion Biomedica Europe LimitedAngion Biomedica Corp.1050 Stewart AvenueGarden City, NY 1153036